1. Medicines
  2. Cardiology
  3. ENTRESTO® (sacubitril/valsartan)
  4. Burden of heart failure

Click here for Prescribing Information

Burden of heart failure

   

Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring1

Modest changes in LVEF may be clinically important; the adjusted risk of CV-related mortality increases two-to eight-fold beyond a >10-unit decline in LVEF (P<0.001).2

Image of an egg timer, representing 10–100x deterioration for cardiac myocytes in failing human hearts compared with healthy hearts.

deterioration for cardiac myocytes in failing human hearts compared with healthy hearts3

approximately 90,000 people in Ireland live with Heart Failure (HF) with 10,000 cases diagnosed each year4,10

 

6x greater risk of death in the first month after just one HF hospitalisation in comparison with non -hospitalised patients.

greater risk of death in the first month after just one HF hospitalisation in comparison with non-hospitalised patients5,6

Image of a heart, representing up to 65% of HFrEF patients may experience sudden cardiac death, even when their symptoms have not worsened.

of HFrEF patients may experience sudden cardiac death, even when their symptoms have not worsened7

 

ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation9

down pointing arrow icon

 

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.9

CV, cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; MoA, mode of action; MRA, mineralocorticoid receptor antagonist; QoL, quality of life.

References:

  1. Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
  2. Strange G, et al. Eur J Heart Fail 2021;23(4):555–563.
  3. Konstantinidis K, Whelan RS, Kitsis RN. Thromb Vasc Biol 2012;32(7):1552–1162.
  4. Cost of Heart Failure Report, December 2015, Data on file
  5. Solomon SD, et al. Circulation 2007;116(13):1482–1487.
  6. Okumura N, et al. Circulation 2016;133(23):2254–2262.
  7. Packer M. Eur Heart J 2020; (41)1757–1763
  8. Health Policy Partnership, Heart Failure Barometer Report, 2019, Data on File.
  9. ENTRESTO Summary of Product Characteristics. Accessed December 2021 at www.medicines.ie
  10. Healthcare Pricing Office (2021) Activity in Acute Public Hospitals in Ireland Annual Report, 2020. Dublin. Health Service Executive. Accessed April 2021 at http://www.hpo.ie/latest_hipe_nprs_reports/HIPE_2020/HIPE_Report_2020.pdf
Rate this content: 
Average: 5 (1 vote)
April 2022 | IE 171968
Cardiology
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.